Medindia11h
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...
The Manila Times13h
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
Le Lézard14h
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2?-bias Bispecific Antibody Fusion Protein) in Melanoma
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
Innovent Receives NMPA Breakthrough Therapy Designation For IBI363 (PD-1/IL-2Α-Bias Bispecific Antibody Fusion Protein) In Melanoma
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
News-Medical.Net on MSN8h
Traditional Chinese medicine targets cholesterol metabolism for cancer treatment
Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat ...
The Manila Times5h
Harbour BioMed Reports Full Year 2024 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ('HBM' or the 'Company'; ...